Emergency Use Authorization to Novavax 2024-2025 Formula Covid-19 vaccine to prevent Covid-19 in individuals aged 12 and older: US FDA

Novavax, Inc. announced that its Novavax Covid-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA) for individuals aged 12 and older. This vaccine, which targets the JN.1 variant, has been recommended by the CDC as of June 27, 2024.

The vaccine will soon be available in numerous locations, including pharmacies and grocers, once vaccine batches are released by the Center for Biologics Evaluation and Research. The EUA is based on data showing that the vaccine provides cross-reactivity against JN.1 and related variants.

The vaccine is not yet FDA-approved but is authorized for emergency use. NVX-CoV2705 is an updated version of Novavax’s prototype vaccine (NVX-CoV2373) and is formulated to target the JN.1 variant using Novavax's recombinant nanoparticle technology and Matrix-M adjuvant.